Matthew W. Davis
Chief Development Officer · Aquestive Therapeutics, Inc.
Individual
- 2025
- Mar 11, 2026
- 2
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew W. Davis files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Daniel Barber - $1.22M in AQST purchases and sales in the last 12 months
- A. Ernest Toth Jr. - $243K in AQST purchases and sales in the last 12 months
- Cassie Jung - $191K in AQST purchases and sales in the last 12 months
- Lori J. Braender - $167K in AQST purchases and sales in the last 12 months
- Julie Krop - $125K in AQST purchases and sales in the last 12 months
- Peter E. Boyd - $124K in AQST purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew W. Davis?
Matthew W. Davis is a corporate insider, tracked as Chief Development Officer of Aquestive Therapeutics, Inc. (AQST). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Matthew W. Davis last file a Form 4?
The most recent primary Form 4 on record is dated 11 March 2026, one of 2 filings going back to 2025.
